Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025 February 25, 2026 Strong margin improvement to 16.3% in FY 2025 Positive growth outlook with continued margin expansion in 2026 New EUR 200 million share buyback
Luxfer Delivers Strong Full-Year 2025 Profitability and Cash Generation February 24, 2026 Portfolio focus and favorable mix drive sustained profitability, enhanced adjusted earnings growth and strong cash flow generation Fourth Quarter 2025 Highlights* Net Sales declined 12.3% to $90.7 million from $103.4 million, while Adjusted Net Sales1 declined 5.5% Net Income of $0.1 million, compared to $3.3 million, and $0.12 per diluted share, with Adjusted Diluted EPS1 of $0.28 down 3.4% from $0.29 Adjusted EBITDA1 of $13.0 million, declined 5.8% Continued execution of previously announced operational excellence initiatives, including the Riverside and Powders Saxonburg centers of excellence, expected to drive improved efficiency and generate approximately $6 million of long-term annual savings Full Year 2025 Highlights* Net Sales declined 1.9% to $384.6 million from $391.9 million, while Adjusted Net Sales1 increased 2.5% Net Income of $13.1 million, or $0.48 per diluted share, compared to $18.3 million and $0.68 per diluted share, with Adjusted Diluted EPS1 of $1.11, up 12.1% from $0.99 Adjusted EBITDA1 of $51.9 million, up 4.2% Delivered strong free cash flow of $26.2 million, reducing net debt to $31.1 million Enhanced portfolio quality and strategic focus following completion of the Graphic Arts sale * Comparative information is relative to prior-year fourth quarter and full year; results exclude discontinued operations 1 Note: Adjusted results exclude Graphic Arts and 2024 legal fee recoveries
IGI Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results and Declares Ordinary Common Share Dividend February 24, 2026 International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today reported financial results for the fourth quarter and full year 2025. Highlights for the fourth quarter and full year 2025 include: (in millions of U.S. Dollars, except percentages and per share information) Quarter Ended December 31, Year Ended December 31, 2025 [...]
Almirall’s 2025 Results February 23, 2026 Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.
Allegion (NYSE: ALLE) Reports Q4, Full-Year 2025 Financial Results, Introduces 2026 Outlook February 17, 2026 High-Single Digit Revenue Growth for the Enterprise and Continued Strength in Americas Non-Residential Quarterly Financial Highlights (All comparisons are year-over-year, unless otherwise noted) Net earnings per share (EPS) of $1.70, up 3.0% compared with $1.65; Adjusted EPS of $1.94, up 4.3% compared with $1.86 Revenues of $1,033.2 million, up 9.3% on a reported basis and up 3.3% on an organic basis Operating margin of 20.3%, compared with 19.5%; Adjusted operating margin of 22.4%, compared with 22.1% Full-Year Financial Highlights (All comparisons are year-over-year, unless otherwise noted) EPS of $7.44, up 9.1% compared with $6.82; Adjusted EPS of $8.14, up 8.1% compared with $7.53 Revenues of $4,067.3 million, up 7.8% on a reported basis and up 4.1% on an organic basis Operating margin of 21.1%, compared with 20.7%; Adjusted operating margin of 23.2%, up 40 basis points compared with 22.8% Available cash flow, which is defined as net cash from operating activities minus capital expenditures, was $685.7 million for 2025, an increase of 17.6% 2026 Full-Year Outlook Highlights Full-year reported revenue growth is estimated to be 5% to 7%, with organic revenue growth estimated to be 2% to 4% Full-year adjusted EPS is estimated to be $8.70 to $8.90 Available cash flow is estimated to be 85% to 95% of adjusted net income
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 February 12, 2026 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The announcement will be followed by [...]
AB InBev Reports Full Year and Fourth Quarter 2025 Results February 12, 2026 Underlying EPS increased by 6% with continued margin expansion and free cash flow generation of 11.3 billion USD
Luxfer Announces Date of Fourth Quarter and Full Year 2025 Earnings Conference Call February 11, 2026 Luxfer Holdings PLC (NYSE: LXFR) (“Luxfer” or the “Company”), a global industrial company innovating niche applications in materials engineering, today announced the details for its fourth quarter and full-year 2025 earnings conference call. Date and time: Wednesday, February 25, 2026, at 8:30 a.m. Eastern Time Luxfer participants: Andy Butcher Chief Executive Officer Steve Webster [...]
IFF Reports Fourth Quarter and Full Year 2025 Results February 11, 2026 Delivered solid top and bottom-line performance & advanced strategic priorities in 2025 Launched sale process for the Food Ingredients segment Continuing to drive financial performance in 2026
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 February 11, 2026 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company. The webcast player and accompanying [...]